Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals Stock Performance
NASDAQ:REGN traded up $0.65 during mid-day trading on Monday, reaching $629.36. 3,887 shares of the company's stock were exchanged, compared to its average volume of 690,586. Regeneron Pharmaceuticals has a one year low of $538.01 and a one year high of $747.42. The firm has a market capitalization of $68.61 billion, a PE ratio of 12.55, a price-to-earnings-growth ratio of 2.19 and a beta of 0.29. The business's fifty day simple moving average is $595.86 and its two-hundred day simple moving average is $636.87. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.39 and a current ratio of 5.12.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Rating) last posted its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share for the quarter, missing analysts' consensus estimates of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The company had revenue of $2.86 billion during the quarter, compared to analyst estimates of $2.80 billion. During the same quarter in the previous year, the business posted $27.97 earnings per share. The company's revenue for the quarter was down 44.4% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals will post 35.9 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research analysts have recently commented on REGN shares. Wells Fargo & Company reduced their price target on Regeneron Pharmaceuticals from $750.00 to $735.00 and set an "overweight" rating for the company in a research report on Friday, June 3rd. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, July 12th. They issued a "neutral" rating and a $625.00 price target for the company. BMO Capital Markets raised their target price on Regeneron Pharmaceuticals from $757.00 to $788.00 and gave the stock an "outperform" rating in a research note on Thursday, August 4th. StockNews.com lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday, July 26th. Finally, Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $619.00 to $625.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 4th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $698.35.
Insiders Place Their Bets
In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $620.91, for a total transaction of $9,313,650.00. Following the completion of the transaction, the director now owns 1,872 shares in the company, valued at approximately $1,162,343.52. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Christine A. Poon sold 15,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $620.91, for a total value of $9,313,650.00. Following the completion of the sale, the director now owns 1,872 shares in the company, valued at approximately $1,162,343.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, July 1st. The shares were sold at an average price of $587.76, for a total transaction of $646,536.00. Following the completion of the sale, the executive vice president now owns 19,644 shares of the company's stock, valued at approximately $11,545,957.44. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,435 shares of company stock worth $31,663,304. 8.99% of the stock is currently owned by insiders.
